For the tide of patent expiration，2010-2015 is the dense period of the original drug patent expiration，This was once the prediction result of a professional institution has been recognized by the world。During this period, nearly 400 are mainly concentrated in breathing、Cardiovascular、Patented drugs in the field of central nervous system，Among them, more than 80 heavy drugs，The amount involved is as high as 200 billion US dollars。

 

  Although major institutions have biased the estimation of the market value of the due drug，But 2012 is the patented drug & ldquo; the year of the disaster & rdquo;，Drugs worth about $ 50 billion in drugs lost patent protection; 2015 is considered to be the most important patent year after 2012，There are more than 40 billion US dollars of patented medicines lost protection。Patent expiration is a heavy innovation for the original research enterprise，It is a historic opportunity for generic drug companies。

 

  In these two iconic patents,，The market share of many companies in many companies is divided by many generic drug companies around the world。So for the world's largest major generic drug country，Which companies are in this & ldquo; patent carnival & rdquo;，This article only takes the top patented patent during the global ranking as an example，Analysis of its division and the situation of domestic companies to seize the market。

 

  [2012] The first climax: & ldquo; patent carnival & rdquo;

 

  1. Bolvi: Plavix, clopidogre

 

  Patent expiration (American patent，The same below): May 2012

 

  Sales in 2011 (Global，The same below): 6.989 billion euros; sales in 2015: 1.929 billion euros

 

  Approve generic drug companies: there is a ladium abroad、Dr. Rei, etc.，Domestic Xinlitai、Lepu Pharmaceutical

 

  Domestic leadership: Xinlitai, market share is about 37%

 

  Bolvi is a new medicine with a priority review identity approved by Sanofi in 1997，Clinical for clinical thrombosis disease，The market is jointly developed by Beltay Schimi Bao and Sanofi，It was the world's second best -selling medicine in the world after many years in a row。

 

  2001 Boli entered the domestic market，For many years, it has formed a double oligopoly competition situation with Thailand's Taijia，2012 Le Pharmaceutical joined the competition。At present, the sales data of the Miner sample hospital hospital，Its domestic sales in 2015 exceeded 1.4 billion yuan。

 

  2. Siroquel/Seroquel XR，Fugaic acid sulfur flat

 

  Patent expiration: March 2012 (Chang Shi)，2017 (slow release)

 

  In 2011 sales: $ 5.828 billion; sales in 2015: $ 1.275 billion

 

  Approve generic drug companies: there is a ladium abroad、Mailan, etc.，domestic Hunan Dongting Pharmaceutical、Suzhou No. 1 Pharmaceutical

 

  Domestic leadership: Hunan Dongting Pharmaceutical，Market share is about 17%

 

  Astrikan's Sirikang Changpi Film was approved by the FDA in 1997 for the treatment of schizophrenia。In 2007, its sustained -release film was approved for listing，After two years, he became a member of the annual sales of one billion US dollars in the club。

 

  2000 Siri Kang's interpretation My stake betting appstake online sports bettingfilm enters the Chinese market，Over the years, its sales occupy the position of the top three of these drugs。Although the market leader of the original research enterprise is difficult to shake，But the share of domestic enterprises continues to increase。Sirui Kang Slow -release Preparation is now available for products，Dani and Sinopharm Group and other companies such as Astrikon and Sinopharm Group are declared，Judgment of the queue of review，The listing time will not be far away。

 

  3. Shun Erning: Singulair，Meng Lu Ste

 

  Patent expiration: August 2012

 

   2011 sales: $ 5.479 billion; sales in 2015: $ 931 million

 

  Approve generic drug companies: there is a ladium abroad、Mailan, etc.，Domestic Rubanbert、Sichuan Okuka

 

  Domestic leadership: Sichuan Dazhi, market share is about 15%

 

  Shun Erning was approved to be listed in 1998，Clinically for asthma，As a Monetic tree of Merhado，Since its listing, it has made tens of billions of dollars in sales。But in just 4 weeks after the first batch of generic drugs entered the market，Its original research drug sales fell sharply 90%，Amazing the huge lethality of the patent expiration to the original medicine。

 

  1999 Shurine entered the domestic market，Domestic tablets and chewing tablets began to be available in 2006，As of now, only two have two approveds。Facing domestic sample hospital sales of nearly 300 million yuan varieties，Many manufacturers waiting for the listing of cakes。

 

  4. Aikoto: Actos, Pinglidone

 

  Patent expiration: August 2012

 

  2011 sales: US $ 3.732 billion; sales in 2015: $ 24 million

 

  Approved generic drug companies: Huasheng abroad、Mailan, etc.，China, China, East China, etc.

 

  Domestic leadership: Beijing Eceanic, market share is about 20%

 

  Aikoto is a new medicine with a priority review of the FDA approved by Takeda in 1999，Sales are jointly carried out by Takeda and Lili Lili，until the end of the cooperation in 2006。Aikoto brings an income of over 100 billion US dollars to Takeda，Until 2014, the U.S. Federal Court jury issued the biggest penalty in the pharmaceutical sector of the Pharmaceutical field of $ 9 billion，Only caused its golden power to quickly decrease。Although this fine later was dramatically reduced to 36.8 million US dollars，But this thrilling offensive and defensive battle is impressive。

 

  5. La Shi: Lexapro，Aisi Pulan

 

  Patent expiration: March 2012

 

  In 2011 sales: 8.492 billion Dan Ying Krony; Sales in 2015: 2.591 billion Dan Ying Krona (only sales data of Lingbei Pharmaceutical)

 

  Approve generic drug companies: there is a ladium abroad、Mailan, etc.，There are Sichuan Coron, etc.

 

  Domestic leadership: Jingwei, Shandong, market share is about 27%

 

  La Shi was approved by FDA in 2002，The approved enterprise is a forest laboratory，Its sales are completed by the Forest Lab and Danish Lingbei。Drugs for treating depression，Get market recognition after listing，In 2003, the number of prescriptions accounted for more than 50%of the new prescriptions of forest companies' antidepressant products。With several acquisitions and acquisitions with the forest laboratory，The data of its responsible sales area shows on the annual report of Eljian，In the first half of 2016, Shipu sold 35.2 million US dollars。

 

  La Shi will enter the country earlier，Lingbei Pharmaceutical and Xi'an Yangsen reached a joint marketing。Subsequent domestic companies Shandong Jingwei and Sichuan Kelon have been approved one after another，After years of fighting，The market share of domestic enterprises is rising rapidly。

 

  6.，缬

 

  Patent expiration: September 2012

 

  In 2011 sales: $ 5.665 billion; sales in 2015: $ 1.284 billion

 

  Approved generic drug companies: Huasheng abroad、Mailan, etc.，Domestic four medicines in Changzhou、Landbert, etc.

 

  Domestic leadership: China Resources Saito (imitation of generations)，Market share is about 3%; Jiangsu Wan Gao (imitated Diger)，Market share is about 12%

 

  1996 and 1998 Novarta's Daiwen and Dai Daiwen were approved，It marks that anti -hypertension drugs enter a new mileage。The 1999 Wen entered China，Fang Fang Daiwen in 2005 was successfully registered。

 

  As the most successful Salin anti -hypertension drug，Daiwen triggered the imitation enthusiasm of domestic enterprises。However, after more than stake sports betting appstake online sports bettingten years of market development，Daowen's domestic enterprise market share is always hovering around 30%，The reason is worth studying。

 

  7 million Ai Ke: Viagra, Westland Never

 

  Patent expiration: March 2012

 

  2011 sales: $ 1.981 billion; sales in 2015: $ 1.708 billion

 

  Approve generic drug companies: there is a ladium abroad、Apotex, etc.，Domestic Baiyun Mountain、Jiangsu Yabang Aibon

 

  Domestic leadership: Baiyunshan, market share ﹤ 1%

 

  Wan Aike is a new medicine approved by the FDA in 1998，Have a priority review identity，Used for erectile dysfunction (ED)，In 2005, it approved its treatment of pulmonary hypertension。Wan Ai can enter China for many years，But the share of state -owned enterprises is so small，Its patent protection of China plays a decisive role。

 

  Since China does not give patent protection to the drug compound before 1993，Therefore, Pfizer applied for a new use patent for the treatment of ED in China，Application number CN94192386.x。Out of misjudgment of patent authorization，As a result, many state -owned enterprises begin to imitate，But September 19, 2001，This patent is authorized，So state -owned enterprises have begun to make invalidation requests on the patent。After 7 years of patent wars，Beijing High Court made a final judgment，Original Research Victory。until May 12, 2014，The expiry of the patent protection period，September 18, the same year，Guangyao Group Bai Yunshan & ldquo; Jin Ge & rdquo; officially got the approval article。

 

  From project to listing，Domestic companies have been fighting for more than ten years，In the case of the original research medicine unified the world，How to get a cup of cake is the focus of corporate thinking。

 

  8. Zhuo Le Ding: Geodon/Zeldox，Ziracone

 

  Patent expiration: March 2012

 

  Sales in 2011: US $ 1.022 billion; Sales in 2014: US $ 24 million (2015 Report Reception)

 

  Approve generic drug companies: Lupin abroad、Yam Dezi, etc.，There are Chongqing St. Huaxi in China、Jiangsu Enhua

 

  Domestic leadership: Chongqing St. Huaxi, market share 24%

 

  Geodon is a new medicine approved by Pfizer in 2001，Europe uses Zeldox as the product name，Clinically for schizophrenia。Domestic enterprises produce Qlasita products earlier，2005 Chongqing St. Huaxi took the lead in obtaining related production approval，Later Jiangsu Enhua also received approval。At present, this product is sold at the domestic level，2 domestic approved enterprises，Not many companies declared。

 

  Summary

 

  Except the above drugs，There are also imported products without domestic generic drugs，and Modotici, who has no imports and no domestic generic drugs，All are the heavy original research medicines in the 2012 patent expiration。

 

  Since the United States is the world's largest pharmaceutical market，Market as a key layout of major enterprises，The expiration of American patents means a sharp decline in profits，But because the major research companies focusing on various markets around the world are different，Some products in Europe、There is a difference in patent expiration date of emerging economies such as Japan and China，As a result, the sales trend of the above products in the following years is very different。

 

  The difference in market share of the above -mentioned heavy drugs from the above -mentioned heavy drugs comes from historical reasons，Many heavy original medicines such as Salutan have not applied for patent protection in my country，or its administrative protection has expired a few years ago，Make domestic generic drug products be available earlier than 2012，This has the timing of expanding the market share to the national product。But with the continuous prosperity of the Chinese pharmaceutical market，Original research enterprises must attach importance to the patent protection of the Chinese market，This makes the independent research and development of domestic enterprises is imperative。

 

  [2015] The second climax: Well worse?

 

  The embarrassment of patent cliff is the pain My stake betting appin the heart of the pharmaceutical stake online sports bettingcompany giant，It has lost heavy losses in 2012，Is it even worse in 2015。Slightly different from 2012，Some biopharmaceuticals in the drugs in 2015，Biotechnology drugs due to many technical difficulties during the production process，Therefore, the impact of such generic drugs on sales is less than chemical。

 

  1. When it comes: Lantus, glycone insulin

 

  Patent expiration: February 2015

 

  Sales of 2015: 6.390 billion euros

 

  Approved generic drug companies: None abroad, Gan Li Pharmaceuticals in China

 

  Domestic leadership: Gan Li Pharmaceutical，Sales of nearly 100 million yuan in 2015

 

  When it comes to the new medicine approved by Sanofi in 2000，Clinically for the treatment of diabetes，It has been very popular since its listing，The sales amount has been above 3 billion euros in recent years，The patents of this drug expired in February and May 2015。2014，Sanofi is the problem of generic drugs that came when they came，Patent litigation with Li Lili，Make the FDA delayed delay of the approval of Lilly products for 30 months。

 

  Beijing Ganli Pharmaceuticals obtained reorganized glycamon insulin approval in 2005，Although it is the same long -acting insulin，and the difference in listing in China is not much different，Perhaps due to the characteristics of biological agents，Sanofi's sales have always been better than national products。Current，There are also enterprises such as Zhuhai Federation and Zhejiang Haizheng actively declare。

 

  2. An Lufan: Abilify, Alizozo

 

  Patent expiration: April 2015

 

  Sales in 2015: 347.5 billion yen

 

  Approval of generic drug companies: Apotex abroad、Siwa, etc.，Domestic Chengdu Kanghong、Chinese and West, etc.

 

  Domestic leadership: Dazhi, Zhejiang, 54%market share

 

  Aleirazole is a new medicine approved by Okasaki Pharmaceutical in Japan in 2002，Sales are jointly completed by Beltay Schimi Bao and Okasuka。As the best -selling anti -schizophrenia medicine for Okasuka，Alilicazole has been on the list for a long time in the world's best -selling medicine list。Although Ishizaka has successfully repelled the patent challenges of Siwa and Apotex，but after the patent expires，The fact that sales fell by 50%also caused the original research enterprise to hurt their brains。

 

  Domestic enterprises began to declare in 2003，2004 Chengdu Kanghong、Zhejiang Dazuka and Shang medicine Chinese and Western China and West have been approved one after another。

 

  3.Namenda: U.S. Pharium Vaitic acid

 

  Patent expiration: April 2015

 

  Sales in 2015: $ 556 million

 

  Approved generic drug companies: AMNEAL abroad、Mailan, etc.，Domestic Federal Pharmaceutical

 

  Domestic leadership: Federal Pharmaceutical, market share 1.24%

 

  Namenda is a new medicine approved by FDA in 2003，Clinically for Alzheimer's disease。2012 Namenda brought $ 1.4 billion to the forest laboratory，A series of mergers and acquisitions that occurred in 2014，This product falls into Eljian's pocket。

 

  2006，CFDA approves the import of Vajrayana in Danish Lingbei。and domestic companies have successively reported since 2003，Until 2013 Federal Pharmaceutical received the first imitation approval。Due to the late listing time，Market expansion progress is relatively slow。

 

  4.Zyvox: Lenitzoa

 

  Patent expiration: May 2015

 

  Sales in 2015: $ 883 million

 

  Approve generic drug companies: there is a ladium abroad、Mailan, etc.，Jiangsu Haosen

 

  Domestic leadership: Jiangsu Haosen, market share ﹤ 1%

 

  zyvox is a new medicine approved by Farcia Puqiang in 2000，Clinically used in the treatment of infection caused by the treatment of Gram -positive bacteria。2003，Famasia Puqiang was acquired by Pfizer，zyvox becomes a product owned by Pfizer。After the patent expires，2015 sales decreased by nearly 40 % compared to the previous year，The region that helps sales from sales comes from China，increased by about 7%。

 

  2007 Pfizer brought Lenitzoa into China，2015 Hamson in Jiangsu Hosanzozoid injection was approved for listing，Market development still takes time。

 

  Summary

 

  Except the above varieties，There are still many heavy medicines that have not entered the domestic patent，Stake Sports BettingRugao Tan expired in November 2015，Global sales of 2015 stake betting app1.212 billion Swiss franc，Domestic enterprises have Zhejiang Tianyu、Beijing Wan Sheng, etc.。There are also some varieties that are neither imported or domestic declarations after the patent expires，such as galamer acetic acid、Non -Ge Si Ting and Palizumab。

 

  I have to talk about the problem of biological similar drugs (especially monoclonal antibodies)。Since the start of the Chinese monoclonal anti -anti -anti -corporate drug research and development is more than ten years later，Therefore, whether it is accumulated in the foundation、R & D investment、There is a lot of gaps with foreign biopharmaceutical companies in science and technology personnel and team management。Eneste developed by Samsung Samsung BIOEPIS、Bio -similar medicines such as Yingfliximab have been approved by Europe，I ran to us in the development of such drugs，In the following years, it is a dense year for the global super -heavy monocular patent patent，How to seize this major opportunity for state -owned enterprises is worth thinking about。